

- [Dossier preparation manuals](#)
- [Q&A](#)
- [Create support request](#)
- [IUCLID user community](#)
- [Additional information](#)
- [Video tutorials](#)

SuperUser EPA/ORD/CCTE/SCDCD

- User Settings
- Logout
- Dashboard
- Substances
- 2-(3-oxazolidinyl)ethyl methacrylat...

**Filtered aggr\_1**

4134c448-2ef5-41d0-8cfd-2235a8930f5b

View Dossiers

Validate

- Export to i6z
- Extract to dataset
- Create component PDF/RTF
- Create document PDF/RTF
- Compare
- Generate report
- Dissemination preview

Type at least 3 characters

REACH Complete  
2-(3-oxazolidinyl)ethyl methacrylate

- 1 General information  
3
- 2 Classification & Labelling and PBT assessment
- 3 Manufacture, use and exposure
- 4 Physical and chemical properties  
17
- 5 Environmental fate and pathways  
6
- 6 Ecotoxicological information  
5
- 7 Toxicological information  
20
  - ef8afd8d-4581-43a2-866c-d158009920d8
  - 7.1 Toxicokinetics, metabolism and distribution  
2

- 7.2 Acute Toxicity  
4
- 7.3 Irritation / corrosion  
5
- 7.4 Sensitisation  
1
- 7.5 Repeated dose toxicity  
2
  - 7.5.1 Repeated dose toxicity: oral  
2
    - 70a137fe-90e3-4aac-a47c-c9134f5e8a04
    - 8c8b5a06-4a59-4883-a5c2-64533e740220
  - 7.5.2 Repeated dose toxicity: inhalation
  - 7.5.3 Repeated dose toxicity: dermal
  - 7.5.4 Repeated dose toxicity: other routes
- 7.6 Genetic toxicity  
3
- 7.7 Carcinogenicity
- 7.8 Toxicity to reproduction  
2
- 7.9 Specific investigations
- 7.10 Exposure related observations in humans
- 7.11 Toxic effects on livestock and pets
- 7.12 Additional toxicological information

- 8 Analytical methods
- 9 Residues in food and feedingstuffs
- 10 Effectiveness against target organisms
- 11 Guidance on safe use
- 12 Literature search
- 13 Assessment reports
- 14 Information requirements
- Inherited templates

UUID 8c8b5a06-4a59-4883-a5c2-64533e740220 ☐ Hide empty fields

- 

  



Administrative data	Data source	Materials and methods	Results and discussion	Overall remarks, attachments
Applicant's summary and conclusion				

Administrative data

Endpoint  
sub-chronic toxicity: oral

Type of information

experimental study

Adequacy of study  
supporting study

☐ Robust study summary

☐ Used for classification

☐ Used for SDS

Study period

Reliability  
2 (reliable with restrictions)

Rationale for reliability incl. deficiencies

Data waiving

Justification for data waiving

Justification for type of information

Attached justification

# Attached justification Reason / purpose Actions

Cross-reference

# Reason / purpose for cross-reference Related information Remarks Actions

Data source

Reference

- study report | Unnamed | 1974 | 1974-10-02

Data access

Data protection claimed

Materials and methods

Test guideline

# Qualifier Guideline Version / remarks Deviations Actions

Principles of method if other than guideline

GLP compliance  
no

Limit test  
no

Test material

Test material information

- Unnamed | Unnamed | 2-(1,3-oxazolidin-3-yl)ethyl 2-methylprop-2-enoate | EC 256-260-2 | 46235-93-2

---

Additional test material information

---

Specific details on test material used for the study

---

Specific details on test material used for the study (confidential)

---

**Test animals**

---

Species  
dog

---

Strain  
Beagle

---

Details on species / strain selection

---

Sex  
male/female

---

Details on test animals or test system and environmental conditions

---

**Administration / exposure**

---

Route of administration  
oral: feed

---

Details on route of administration

---

Vehicle

---

Details on oral exposure

---

Analytical verification of doses or concentrations

---

Details on analytical verification of doses or concentrations

---

Duration of treatment / exposure  
90 day

---

Frequency of treatment

---

**Doses / concentrations**

---

# Dose / conc. Remarks Actions

---

No. of animals per sex per dose

---

Control animals

---

Details on study design

---

Positive control

---

**Examinations**

---

Observations and examinations performed and frequency

---

Sacrifice and pathology

---

Optional endpoint(s)

---

Other examinations

---

---

## Statistics

---

### Any other information on materials and methods incl. tables

---

## Results and discussion

---

### Results of examinations

---

#### Clinical signs

---

##### Description (incidence and severity)

---

#### Mortality

---

##### Description (incidence)

---

#### Body weight and weight changes

---

##### Description (incidence and severity)

---

#### Food consumption and compound intake (if feeding study)

---

##### Description (incidence and severity)

---

#### Food efficiency

---

##### Description (incidence and severity)

---

#### Water consumption and compound intake (if drinking water study)

---

##### Description (incidence and severity)

---

#### Ophthalmological findings

---

##### Description (incidence and severity)

---

#### Haematological findings

---

##### Description (incidence and severity)

---

#### Clinical biochemistry findings

---

##### Description (incidence and severity)

---

#### Endocrine findings

---

##### Description (incidence and severity)

---

#### Urinalysis findings

---

##### Description (incidence and severity)

---

#### Behaviour (functional findings)

---

##### Description (incidence and severity)

---

#### Immunological findings

---

##### Description (incidence and severity)

---

#### Organ weight findings including organ / body weight ratios

---

##### Description (incidence and severity)

---

Gross pathological findings

Description (incidence and severity)

Neuropathological findings

Description (incidence and severity)

Histopathological findings: non-neoplastic

Description (incidence and severity)

Histopathological findings: neoplastic

Description (incidence and severity)

Other effects

Description (incidence and severity)

Details on results

Effect levels

# Key result Dose descriptor Effect level Based on Sex Basis for effect level Remarks on result Actions 1

☐ Key result

Dose descriptor

NOEL

Effect level

2 mg/kg bw/day (nominal)

Based on

test mat.

Sex

male/female

Basis for effect level

• clinical biochemistry

• haematology

Remarks on result

Target system / organ toxicity

# Key result Critical effects observed Lowest effective dose / conc. System Organ Treatment related Dose response relationship Relevant for humans Actions

Any other information on results incl. tables

Overall remarks, attachments

Overall remarks

Attachments

# Type Attached (confidential) document Attached (sanitised) documents for publication Remarks Actions

Illustration (picture/graph)

Applicant's summary and conclusion

Conclusions

---

## Executive summary

TOP



- Dashboard
- Substances
- Mixtures / Products
- Articles
- Categories

## Toolbox

- Template
- Manage Reports

## Inventory manager

- Contact
- Legal entity
- Sites
- Reference substance
- Test material
- Literature reference

## User management

- User Settings
- Users
- Roles

## About IUCLID

- About
- Help